female infertility
Conditions
Interventions
Salidroside group :he salidroside group began to take oral Salidroside capsules (Tibet Gaoyuan 'an Biotechnology Development Co., LTD.) on the day of entering the COS cycle, once a day, 2 capsules eac
blank control group:The blank control group did not take Rhodiola rosea capsules orally after entering the COS cycle.
Sponsors
The Second Hospital of Shandong University
Eligibility
Sex/Gender
Female
Age
35 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1. Age >= 35 years and < 40 years 2. Those scheduled for the first or second cycle of IVF, ICSI, or donor sperm IVF 3. Meeting the 2016 Poseidon poor prognosis diagnostic criteria: 1-9 retrieved oocytes in the previous cycle with a conventional ovulation induction protocol, or bilateral ovarian AFC < 5 or AMH < 1.2 ng/ml (determined within the last six months)
Exclusion criteria
Exclusion criteria: 1. Patients with coagulation disorders 2. Patients with a history of abnormal uterine bleeding 3. Patients with hydrosalpinx confirmed by B-ultrasound and HSG 4. Patients with uterine malformations (unicornuate uterus, septate uterus) or a history of intrauterine adhesions 5. Patients with >=3 spontaneous abortions in the past 6. Patients with contraindications to assisted reproductive technology or pregnancy 7. Patients who have taken or are currently taking drugs containing salidroside 8. Patients whose controlled ovarian stimulation protocol is PPOS protocol, luteal phase ovulation induction protocol, or continuous stimulation protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Continuous pregnancy rate; | — |
Countries
China
Contacts
Public ContactCuiLinlin
The Second Hospital of Shandong University
Outcome results
None listed